Nurix Therapeutics Inc
NASDAQ:NRIX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.8
28.14
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Nurix Therapeutics Inc
Wall Street
Price Targets
NRIX Price Targets Summary
Nurix Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
NRIX
is 31.82 USD
with a low forecast of 16.16 USD and a high forecast of 43.05 USD.
NRIX Last Price Targets
Nurix Therapeutics Inc
The latest public price target was made on Oct 24, 2024 by
David Dai
from
UBS
,
who expects
NRIX
stock to
rise by 56%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
David Dai
UBS
|
35
USD
Upside 56% |
4 weeks ago
Oct 24, 2024
|
UBS Starts Nurix (NRIX) at Buy
StreetInsider
|
|
Robert Burns
H.C. Wainwright
|
30
USD
Upside 33% |
1 month ago
Oct 21, 2024
|
Nurix (NRIX) PT Raised to $30 at H.C. Wainwright
StreetInsider
|
Matthew Biegler
Oppenheimer
|
35
USD
Upside 56% |
1 month ago
Oct 15, 2024
|
Nurix Therapeutics price target raised to $35 from $30 at Oppenheimer
TheFly
|
Derek Archila
Wells Fargo
|
32
USD
Upside 42% |
1 month ago
Oct 15, 2024
|
Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
StreetInsider
|
Stephen Willey
Stifel Nicolaus
|
34
USD
Upside 51% |
1 month ago
Oct 14, 2024
|
Nurix (NRIX) PT Raised to $34 at Stifel
StreetInsider
|
Roger Song
Jefferies
|
41
USD
Upside 82% |
1 month ago
Oct 11, 2024
|
This Amazon Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Benzinga
|
Brian Skorney
Robert W. Baird
|
26
USD
Upside 16% |
2 months ago
Sep 5, 2024
|
Nurix Therapeutics transferred with an Outperform at Baird
TheFly
|
|
Matthew Biegler
Oppenheimer
|
27
USD
Upside 20% |
3 months ago
Aug 14, 2024
|
Nurix (NRIX) PT Raised to $27 at Oppenheimer
StreetInsider
|
Gregory Renza
RBC Capital
|
26
USD
Upside 16% |
4 months ago
Jun 27, 2024
|
Nurix (NRIX) PT Raised to $26 at RBC Capital
StreetInsider
|
|
Robert Burns
H.C. Wainwright
|
26
USD
Upside 16% |
5 months ago
Jun 18, 2024
|
Nurix (NRIX) PT Raised to $26 at H.C. Wainwright
StreetInsider
|
Tyler Van Buren
Piper Sandler
|
35
USD
Upside 56% |
5 months ago
Jun 5, 2024
|
Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)
StreetInsider
|
|
Gregory Renza
RBC Capital
|
23
USD
Upside 2% |
7 months ago
Apr 11, 2024
|
Nurix (NRIX) PT Raised to $23 at RBC Capital
StreetInsider
|
|
Joel Beatty
Robert W. Baird
|
25
USD
Upside 11% |
7 months ago
Apr 11, 2024
|
Nurix (NRIX) PT Raised to $25 at Baird
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is NRIX's stock price target?
Price Target
31.82
USD
According to Wall Street analysts, the average 1-year price target for
NRIX
is 31.82 USD
with a low forecast of 16.16 USD and a high forecast of 43.05 USD.
What is Nurix Therapeutics Inc's Revenue forecast?
Projected CAGR
14%
For the last 4 years the
compound annual growth rate for
Nurix Therapeutics Inc's revenue is
25%.
The projected
CAGR
for the next 4 years is
14%.
You don't have any saved screeners yet
